Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

An active form of vitamin D and weekly bisphosphonates were mainly used for treatment (Table 1).Characteristics of patients before and after propensity score matchingFeb 2018: Feb 2020Mar 2020: Mar 2022SMDn142,461142,461Age84.7 ± 7.684.7 ± 7.70.0008GenderMen30,713 (21.6)30,742 (21.6)0.0005Women111,748 (78.4)111,719 (78.4)ComorbiditiesHypertension54,650 (38.4)54,575 (38.3)0.0011Dementia32,634 (22.9)32,701 (23.0)0.0011Diabetes26,422 (18.6)26,351 (18.5)0.0013Cerebrovascular disease14,039 (9.9)13,983 (9.8)0.0013Ischemic heart disease10,888 (7.6)10,815 (7.6)0.0019Chronic renal dysfunction8332 (5.9)8179 (5.7)0.0046Chronic lung disease2066 (1.5)1970 (1.4)0.0057p valueWaiting days before surgery3.47 ± 3.603.17 ± 3.26 < 0.001※General Anesthesia86,503 (60.7)89,603 (62.9) < 0.001ICU admission5985 (4.2)6304 (4.4)0.003Anticoagulant treatment70,157 (49.3)70,913 (49.8)0.005Edoxaban38,188 (26.8)41,077 (28.8) < 0.001Fondaparinux1759 (1.2)1515 (1.1) < 0.001Enoxaparin5109 (3.6)3388 (2.4) < 0.001Apixaban4166 (2.9)4698 (3.3) < 0.001Clopidogrel7642 (5.4)8145 (5.7) < 0.001Aspirin17,307 (12.2)16,290 (11.4) < 0.001Warfarin5174 (3.6)3954 (2.8) < 0.001Osteoporosis treatment38,561 (27.1)40,367 (28.3) < 0.001Bisphosphonates15,157 (10.6)17,033 (12.0) < 0.001Teriparatide2377 (1.7)1937 (1.5) < 0.001Denosumab540 (0.4)599 (0.4)0.085Active form of Vitamin D27,861 (19.6)29,953 (21.0) < 0.001SERM2091 (1.5)1867 (1.3) < 0.001Age and waiting days before surgery are shown as mean ± standard deviation; Data showed No. (%) with data except for Age and waiting daysP values of < 0.001 are considered significant by the Student’s test and χ2 testSMD means standard mean difference; ICU means intensive care unit; SERM means selective estrogen receptor modulator※ Student t test

Source: Participants. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Increased complications of proximal femur fractures during the COVID-19 pandemic: a nationwide medical claims database study in Japan

Study design awaiting verification · Journal of Bone and Mineral Metabolism · 2025

Original publication title

Increased complications of proximal femur fractures during the COVID-19 pandemic: a nationwide medical claims database study in Japan

Hidetatsu Tanaka; Kunio Tarasawa; Yu Mori; Kiyohide Fushimi; Kenji Fujimori; Toshimi Aizawa

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

These findings alert healthcare professionals and patients to the elevated complications, especially PE rate for proximal femoral fracture with COVID-19 positive.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, and mortality increases in elderly patients with comorbidities. This study aims to examine the in-hospital complications and mortality for elderly patients with proximal femur fractures during the COVID-19 pandemic or countermeasure periods.

Source: Introduction

Abstract: What methods does the paper describe?

The proximal femur fractures undergoing surgery during the COVID-19 pandemic or countermeasure period were compared with the pre-pandemic in a Japanese national inpatient data. The assessed outcomes were the development of pneumonia, deep vein thrombosis (DVT), pulmonary embolism (PE), and mortality during hospitalization in two periods, and those for COVID-19-positive patients.

Source: Materials and methods

Abstract: Results

A total of 284,922 proximal femur fractures aged over 65 years were included. In the COVID-19 pandemic period compared to the pre-pandemic, the odds of pneumonia, DVT, PE, and mortality decreased to 0.942 (95% confidence interval [CI]: 0.901 − 0.986, P = 0.0102) and 0.839 (95% CI: 0.745 − 0.946, P = 0.004), increased to 1.153 (95% CI: 1.112 − 1.195, P < 0.001), and 1.048 (95% CI: 0.982 − 1.118, P = 0.1554), respectively. For COVID-19 positivity at admission, the odds of PE increased significantly to 12.95 (95% CI: 8.795 − 19.06, P < 0.001).

For COVID-19 positivity during hospitalization, the odds of pneumonia and mortality were increased to 2.896 (95% CI: 1.820 − 4.608, P < 0.001) and 6.303 (95% CI: 3.440 − 11.55, P < 0.001), respectively.

Source: Results

Abstract: Conclusion

These findings alert healthcare professionals and patients to the elevated complications, especially PE rate for proximal femoral fracture with COVID-19 positive.

Source: Conclusion
Authors’ abstract

Introduction

Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, and mortality increases in elderly patients with comorbidities. This study aims to examine the in-hospital complications and mortality for elderly patients with proximal femur fractures during the COVID-19 pandemic or countermeasure periods.

Materials and methods

The proximal femur fractures undergoing surgery during the COVID-19 pandemic or countermeasure period were compared with the pre-pandemic in a Japanese national inpatient data. The assessed outcomes were the development of pneumonia, deep vein thrombosis (DVT), pulmonary embolism (PE), and mortality during hospitalization in two periods, and those for COVID-19-positive patients.

Results

A total of 284,922 proximal femur fractures aged over 65 years were included. In the COVID-19 pandemic period compared to the pre-pandemic, the odds of pneumonia, DVT, PE, and mortality decreased to 0.942 (95% confidence interval [CI]: 0.901 − 0.986, P = 0.0102) and 0.839 (95% CI: 0.745 − 0.946, P = 0.004), increased to 1.153 (95% CI: 1.112 − 1.195, P < 0.001), and 1.048 (95% CI: 0.982 − 1.118, P = 0.1554), respectively. For COVID-19 positivity at admission, the odds of PE increased significantly to 12.95 (95% CI: 8.795 − 19.06, P < 0.001).

For COVID-19 positivity during hospitalization, the odds of pneumonia and mortality were increased to 2.896 (95% CI: 1.820 − 4.608, P < 0.001) and 6.303 (95% CI: 3.440 − 11.55, P < 0.001), respectively.

Conclusion

These findings alert healthcare professionals and patients to the elevated complications, especially PE rate for proximal femoral fracture with COVID-19 positive.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00774-025-01611-0.

Publication and source details

Original title: Increased complications of proximal femur fractures during the COVID-19 pandemic: a nationwide medical claims database study in Japan

Hidetatsu Tanaka; Kunio Tarasawa; Yu Mori; Kiyohide Fushimi; Kenji Fujimori; Toshimi Aizawa

Journal of Bone and Mineral Metabolism · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:41:13.777933+00:00

DOI: 10.1007/s00774-025-01611-0 · PMC12620312